Spyre Therapeutics, Inc. (SYRE)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Spyre Therapeutics, Inc. reported revenue of $0. The company ran a net loss. It held $777.78M in total assets against $62.55M in total liabilities.
Key ratios (FY2025)
-21.7%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $886.0K | $2.33M | $18.74M | $0 | $0 | $3.89M | $5.21M | $4.63M |
| Operating Income | -$209.56M | -$208.57M | -$242.30M | -$84.78M | -$65.65M | -$81.48M | -$80.33M | -$45.46M | -$27.68M | -$21.91M |
| Net Income | -$155.20M | -$208.02M | -$338.79M | -$83.81M | -$65.80M | -$80.89M | -$78.25M | -$44.35M | -$27.24M | -$21.70M |
| EPS (Diluted) | — | — | $13.76 | $-24.86 | $-25.02 | $-1.52 | — | — | — | — |
| Total Assets | $777.78M | $608.48M | $341.86M | $71.14M | $109.93M | $161.62M | $83.18M | $77.74M | $56.08M | $67.06M |
| Total Liabilities | $62.55M | $90.68M | $73.29M | $20.84M | $25.98M | $21.79M | $23.10M | $10.31M | $5.74M | $4.10M |
| Shareholders' Equity | $715.24M | $517.80M | $184.02M | $50.30M | $83.94M | $139.83M | $60.08M | $67.43M | $50.34M | $62.97M |
| Cash & Equivalents | $85.72M | $89.42M | $188.89M | $34.86M | $15.14M | $90.09M | $19.25M | $22.46M | $12.82M | $47.75M |
| Operating Cash Flow | -$169.25M | -$157.41M | -$99.91M | -$80.14M | -$53.72M | -$75.78M | -$65.69M | -$32.19M | -$24.61M | -$18.84M |
| Capital Expenditures | — | $0 | $0 | $38.0K | $573.0K | $4.28M | $1.49M | $422.0K | $619.0K | $212.0K |
| Shares Outstanding | 78.19M | 60.26M | 36.06M | 2.61M | 49.36M | 47.96M | 29.08M | 24.14M | 16.67M | 13.43M |